(PharmaNewsWire.Com, July 14, 2021 ) The global hemodynamic monitoring systems market is expected to reach USD 1,167.4 million by 2023 from an estimated USD 857.8 million in 2018, at a CAGR of 6.4%. Factors such as technological advancements in hemodynamic monitoring systems, increasing research into hemodynamic monitoring systems, influx of VC funding, rising prevalence of cardiovascular diseases & diabetes, rising geriatric population & growing number of surgeries, awareness initiatives by industry players, and government focus on critical care infrastructure & services are driving the growth of the hemodynamic monitoring systems market.
In addition, growing demand for patient monitoring devices in non-hospital settings and the emerging economies (such as China, India, Brazil, and Mexico) are expected to offer lucrative growth opportunities for market players in the hemodynamic monitoring systems market. However, a risk associated with invasive hemodynamic monitoring, such as sepsis, bleeding, hemorrhage, thrombosis, air embolism, and pulmonary capillary necrosis is expected to restrain the growth of this market. Moreover, increasing pricing pressure on market players, limited patient awareness related to disease diagnosis, and dearth of skilled professionals are adversely impacting the growth of the market.
By type, noninvasive hemodynamic monitoring systems segment is expected to grow at the highest CAGR during the forecast period
The noninvasive hemodynamic monitoring systems segment is expected to grow at the highest CAGR during the forecast owing to the reduction of staffing costs, treatment expenses, and hospital stay; rising incidence of respiratory disorders; fewer complications of noninvasive hemodynamic monitoring as compared to invasive methods; and better portability, ease of use, and better precision.
Monitors segment to witness the highest growth in the forecast period
The monitors segment is expected to grow at the highest CAGR during the forecast owing to the increasing prevalence of CVD; technological advancements in monitoring systems; increasing funding by government authorities for improving patient-centered care, safety, and efficiency; and the ability of hemodynamic monitors to improve cath lab efficiency.
By geography, Asia Pacific (APAC) to register the highest CAGR in the forecast period
The APAC region comprising Japan, China, India, and Rest of Asia Pacific offers high-growth opportunities for players in the hemodynamic monitoring systems market. Some of the factors driving market growth in the APAC region are Japan’s growing healthcare industry; extensive government reimbursement coverage for critical cardiac procedures; improving healthcare infrastructure in India and China; high diabetes prevalence in Vietnam, Singapore, Malaysia, China, and India; and government initiatives in Australia and Singapore. Increasing penetration in the high-growth Asia Pacific market will prove to be an effective growth strategy for companies focusing on increasing their shares in the global hemodynamic monitoring systems market.
Recent Developments In March 2018, Edwards Lifesciences launched Acumen Hypotension Prediction Index (HPI) software in the US. In February 2018, LiDCO Group had an agreement with Spacelabs Healthcare SAS to distribute LiDCO products in France. In January 2018, Koninklijke Philips launched IntelliVue X3. In January 2018, The University Teaching Hospital (US) incorporated Deltex’s Oesophageal Doppler Monitoring (ODM) system.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
